CA SB 6
in committeeControlled substances: xylazine.
California · 2025-2026 Regular Session · upper
Quick answers
Did CA SB 6 pass?
Not yet. CA SB 6 is in committee as of 2025-08-29 and has not come to a final vote. Latest recorded action (2025-08-29): August 29 hearing: Held in committee and under submission.
What is CA SB 6 about?
Existing law, the California Uniform Controlled Substances Act, categorizes controlled substances into 5 schedules and places the greatest restrictions on those substances contained in Schedule I. Under existing law, the substances in Schedule I are deemed to have a high potential for abuse and no accepted medical use while substances in Schedules II through V are substances that have an accepted medical use, but have the potential for abuse. Existing law restricts the prescription, furnishing, possession, sale, and use of controlled substances, and makes a violation of those laws a crime, except as specified. Existing law defines drug paraphernalia and prohibits, among other things, the manufacture, sale, and possession, as specified, of drug paraphernalia. Existing law excludes from these prohibitions any testing equipment that is designed, marketed, used, or intended to be used to analyze a substance for the presence of fentanyl, ketamine, gamma hydroxybutyric acid, or any analog of fentanyl. This bill would add xylazine to the list of Schedule III substances, as specified. If an animal drug containing xylazine that has been approved under the federal Food, Drug and Cosmetic Act is not available for sale in California, the bill would create an exception for a substance that is intended to be used to compound an animal drug, as specified. The bill would exclude from the prohibitions on paraphernalia any testing equipment to analyze a substance for the presence of xylazine. By creating a new crime, the bill would impose a state-mandated local program. The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement. This bill would provide that no reimbursement is required by this act for a specified reason.
Who sponsors CA SB 6?
Ashby is the primary sponsor of CA SB 6.
Description
Existing law, the California Uniform Controlled Substances Act, categorizes controlled substances into 5 schedules and places the greatest restrictions on those substances contained in Schedule I. Under existing law, the substances in Schedule I are deemed to have a high potential for abuse and no accepted medical use while substances in Schedules II through V are substances that have an accepted medical use, but have the potential for abuse. Existing law restricts the prescription, furnishing, possession, sale, and use of controlled substances, and makes a violation of those laws a crime, except as specified. Existing law defines drug paraphernalia and prohibits, among other things, the manufacture, sale, and possession, as specified, of drug paraphernalia. Existing law excludes from these prohibitions any testing equipment that is designed, marketed, used, or intended to be used to analyze a substance for the presence of fentanyl, ketamine, gamma hydroxybutyric acid, or any analog of fentanyl. This bill would add xylazine to the list of Schedule III substances, as specified. If an animal drug containing xylazine that has been approved under the federal Food, Drug and Cosmetic Act is not available for sale in California, the bill would create an exception for a substance that is intended to be used to compound an animal drug, as specified. The bill would exclude from the prohibitions on paraphernalia any testing equipment to analyze a substance for the presence of xylazine. By creating a new crime, the bill would impose a state-mandated local program. The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement. This bill would provide that no reimbursement is required by this act for a specified reason.
- Introduced
- 2024-12-02
- Latest action
- 2025-08-29 — August 29 hearing: Held in committee and under submission.
- Bill type
- bill
- Last updated
- —
Subjects
Sponsors
- Ashbyauthor
Committees
Not provided by source.
Action timeline
2024-12-02
Introduced. Read first time. To Com. on RLS. for assignment. To print.
introduction,reading-1,referral-committee
2024-12-03
From printer. May be acted upon on or after January 2.
2025-01-29
Referred to Com. on PUB. S.
referral-committee
2025-03-07
Set for hearing March 25.
2025-03-25
From committee: Do pass and re-refer to Com. on APPR. (Ayes 6. Noes 0. Page 532.) (March 25). Re-referred to Com. on APPR.
committee-passage,committee-passage-favorable,referral-committee
2025-03-28
Set for hearing April 7.
2025-04-07
April 7 hearing: Placed on APPR. suspense file.
2025-05-16
Set for hearing May 23.
2025-05-23
Read second time. Ordered to third reading.
reading-1,reading-2,reading-3
2025-05-23
From committee: Do pass. (Ayes 6. Noes 0. Page 1187.) (May 23).
committee-passage,committee-passage-favorable
2025-06-03
Read third time. Passed. (Ayes 38. Noes 0. Page 1472.) Ordered to the Assembly.
passage,reading-1,reading-3
2025-06-04
In Assembly. Read first time. Held at Desk.
reading-1
2025-06-09
Referred to Com. on PUB. S.
referral-committee
2025-07-02
From committee: Do pass and re-refer to Com. on APPR. (Ayes 9. Noes 0.) (July 1). Re-referred to Com. on APPR.
committee-passage,committee-passage-favorable,referral-committee
2025-07-16
July 16 set for first hearing. Placed on APPR. suspense file.
2025-08-29
August 29 hearing: Held in committee and under submission.
Versions
Documents
- application/pdf
- text/html
- application/pdf(no extracted text yet)
- application/pdf(no extracted text yet)
- application/pdf(no extracted text yet)
- application/pdf(no extracted text yet)
- application/pdf(no extracted text yet)
Votes
Do pass, but first be re-referred to the Committee on [Appropriations]
2025-03-25 · pass · 6-0
Member-level votes (6)
- Arreguín: yes
- Caballero: yes
- Pérez: yes
- Gonzalez: yes
- Wiener: yes
- Seyarto: yes
Placed on suspense file
2025-04-07 · pass · 7-0
Member-level votes (7)
- Richardson: yes
- Cabaldon: yes
- Grayson: yes
- Caballero: yes
- Seyarto: yes
- Wahab: yes
- Dahle: yes
Do pass
2025-05-23 · pass · 6-0
Member-level votes (7)
- Caballero: yes
- Seyarto: yes
- Wahab: yes
- Cabaldon: yes
- Richardson: yes
- Grayson: yes
- Dahle: other
3rd Reading
2025-06-03 · pass · 38-0
Member-level votes (40)
- Valladares: yes
- Gonzalez: yes
- Choi: yes
- McNerney: yes
- Weber Pierson: yes
- Becker: yes
- Laird: yes
- Ashby: yes
- Richardson: yes
- Cervantes: yes
- Padilla: yes
- Stern: yes
- Durazo: yes
- Arreguín: yes
- Seyarto: yes
- Niello: yes
- Cortese: yes
- Hurtado: yes
- Pérez: yes
- Grove: yes
- Cabaldon: yes
- Dahle: yes
- Grayson: yes
- Allen: yes
- Menjivar: yes
- Strickland: yes
- Wiener: yes
- Archuleta: yes
- Alvarado-Gil: yes
- McGuire: yes
- Blakespear: yes
- Jones: yes
- Wahab: yes
- Limón: yes
- Caballero: yes
- Ochoa Bogh: yes
- Rubio: yes
- Umberg: yes
- Reyes: other
- Smallwood-Cuevas: other
Do pass and be re-referred to the Committee on [Appropriations]
2025-07-01 · pass · 9-0
Member-level votes (9)
- Alanis: yes
- Schultz: yes
- Mark González: yes
- Harabedian: yes
- Ramos: yes
- Nguyen: yes
- Sharp-Collins: yes
- Haney: yes
- Lackey: yes
Related bills
No related bills recorded for this bill.
Official source
Attribution
Data from openstates_bulk_csv, retrieved 2026-07-24T01:34:27.960412Z
Inspect retained evidence for changes recorded after evidence tracking began:
Use this data
Every field on this page is available from the free public API — no key or licence required. Fetch this bill as JSON: GET /api/v1/bills?jurisdiction=CA&identifier=SB 6. See the API docs or the MCP server for AI assistants.
Known limitations
- Sponsor party and chamber affiliation are not yet captured by this API.
- Committee referrals are not yet captured.
- Some documents have no extracted text yet, so version comparison may be limited.
See the methodology page for data sources and limitations.